Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

191 sites for NCT04821622

ATM Loss, +27 more biomarkers

Prostate Adenocarcinoma

enzalutamide, +1 more drug

hormone therapy, +1 more type

A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

315 sites for NCT04497844

ATM Loss, +61 more biomarkers

Prostate Adenocarcinoma

abiraterone, +2 more drugs

hormone therapy, +1 more type

Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)

106 sites for NCT03742895

ATM Loss, +62 more biomarkers

Breast Carcinoma, +2 more conditions

olaparib

targeted therapy

Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007)

116 sites for NCT04123366

ATM Loss, +27 more biomarkers

Breast Carcinoma, +2 more conditions

olaparib, +1 more drug

immunotherapy, +1 more type

Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations

259 sites for NCT03609216

ARID1A Loss, +122 more biomarkers

Bladder Urothelial Carcinoma

chemoradiotherapy, +6 more drugs

chemotherapy, +3 more types

Pembrolizumab, Olaparib, and Temozolomide for People With Glioma

7 sites for NCT05188508

ATM Loss, +31 more biomarkers

Glioma

olaparib, +2 more drugs

chemotherapy, +2 more types

A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets)

6 sites for NCT03767075

ATM Loss, +94 more biomarkers

Malignant Solid Tumor

atezolizumab

immunotherapy

Efficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid Tumors

1 site for NCT04276376

ATM Loss, +27 more biomarkers

Adenocarcinoma of the Gastroesophageal Junction, +6 more conditions

atezolizumab, +1 more drug

immunotherapy, +1 more type

Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer

1 site for NCT04849364

AKT1 Amplification, +141 more biomarkers

Invasive Breast Carcinoma

atezolizumab, +3 more drugs

chemotherapy, +2 more types

Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation

3 sites for NCT04890613

ATM Loss, +28 more biomarkers

Breast Carcinoma, +5 more conditions

pidnarulex

targeted therapy

A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors

1 site for NCT04826341

ATM Loss, +64 more biomarkers

Malignant Solid Tumor, +1 more condition

berzosertib, +1 more drug

chemotherapy, +1 more type

Maintenance Niraparib and Dostarlimab in Advanced Cholangiocarcinoma

1 site for NCT04895046

ARID1A Loss, +39 more biomarkers

Bile Duct Adenocarcinoma, +1 more condition

dostarlimab, +1 more drug

immunotherapy, +1 more type